Pregnancy Related Clinical Trial
— MMIPOfficial title:
Elucidating the Dynamics and Impact of the Gut Microbiome on Maternal Nutritional Status During Pregnancy
This study is being conducted to investigate how a mother's nutritional status and her gut microbiome during pregnancy contribute to the birth outcomes and health of her baby. The gut microbiome is the totality of microorganisms (e.g. bacteria, viruses, fungi) living in the gastrointestinal tract. This study will focus on pregnant women, 24 years and younger living in the Toronto and greater Toronto area. The focus is on younger women due to their vulnerability to undernutrition. Pregnant participants, and upon delivery, their newborns will be followed throughout pregnancy and for a year afterwards. Throughout this period, the investigators will collect stool samples, rectal swabs, blood samples, health assessments, nutritional and dietary assessments and birth/ labour details. The goal is to define the relationship between a mother's nutritional status and her microbiome dynamics during pregnancy and how they contribute to the birth outcomes and growth of her newborn. With the hypothesis that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.
Status | Recruiting |
Enrollment | 800 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A to 24 Years |
Eligibility | Inclusion Criteria: 1. Consent provided 2. Participant is between 8-20 weeks post-conception 3. Female aged 24 years of age and younger 4. Confirmation of pregnancy 5. Intend to comply with study procedures and follow up Exclusion Criteria: 1. Women who do not meet the enrolment age criteria 2. Women who are 20 + weeks post-conception 3. Women who have taken antibiotics within the past 3 months Note: it is common practice to give the mother penicillin in perinatal period if they are GBS positive; because this is standardized across the board it would not act as an exclusion factor. |
Country | Name | City | State |
---|---|---|---|
Canada | St. Michael's Hospital | Toronto | |
Canada | The Hospital for Sick Children | Toronto |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children | Aga Khan University, Canadian Institutes of Health Research (CIHR), Dalhousie University, National Institute of Allergy and Infectious Diseases (NIAID), Unity Health Toronto, University of Alberta, University of Calgary, University of Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess if alterations of the microbiota in the maternal gut (dysbiosis) are associated with changes in maternal gestational weight gain. | The primary endpoint will be the change in maternal gestational weight gain (GWG) during pregnancy, measured between the first (8-20 weeks post-conception) and second time point (30-34 weeks post conception). | 8-20 weeks post-conception, 30-34 weeks post conception | |
Secondary | Anthropometrics: Maternal BMI | calculated using weight and height; BMI = kg/m2 | 8-20 weeks post-conception, 30-34 weeks post-conception, delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum | |
Secondary | Anthropometrics: Maternal middle upper arm circumference | Measured in cm | 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum,and 12 months post-partum | |
Secondary | Anthropometrics: Maternal triceps skinfold thickness | Measured in cm | 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum, and 12 months post-partum | |
Secondary | Anthropometrics: Maternal height | Measured in cm | 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post partum | |
Secondary | Anthropometrics: Maternal weight | Measured in kg | 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post-partum | |
Secondary | Maternal blood biomarkers | Concentration of HB + MCV, ferritin, and CRP | 8-20 weeks post-conception, 30-34 weeks post-conception, and 12 months post-partum | |
Secondary | Infant blood biomarkers | Concentration of HB + MCV, ferritin, and CRP | 12 months | |
Secondary | Infant sex | Female or Male | Determined at delivery | |
Secondary | Infant morbidity | Assessed through infant health assessment questionnaires | 3 months, 6 months and 12 months | |
Secondary | Maternal morbidity | Assessed through health assessment questionnaires | 8-20 weeks post-conception, 30-34 weeks post-conception, 3 months post-partum, 6 months post-partum and 12 months post-partum | |
Secondary | Infant growth: weight | Measured in kg | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Infant growth: length | Measured in cm | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Infant growth: head circumference | Measured in cm | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Infant growth: mid upper arm circumference | Measured in cm | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Infant growth: triceps skinfold thickness | Measured in cm | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Infant Gestational age | Will be documented at baseline visit. | 8-20 weeks post conception | |
Secondary | Breast feeding: amount and initiation of complementary feeding | Based off of WHO 2010 Guidelines: Indicators for assessing infant and young child feeding practices (Part 2 Measurement) | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Maternal age | 24 years or younger | Documented at 8-20 weeks post-conception | |
Secondary | Reported maternal medication use | [Questionnaire] | 8-20 weeks post-conception, 30-34 weeks post-conception, within 24 hours of delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum | |
Secondary | Reported Infant medication use | [Questionnaire] | within 24 hours of birth, 3 months, 6 months and 12 months | |
Secondary | Maternal dietary intake | Assessed through ASA 24 HR Dietary Recall system, completed 2x each time point | 8-20 weeks post conception, 30-34 weeks post conception and 12 months post partum | |
Secondary | Dietary diversity | Minimum Dietary Diversity Score for Women (MDD-W) | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post-partum and 12 months post partum | |
Secondary | Household annual food insecurity | Food insecurity will be assessed using the Household Food Insecurity Access Scale (HFIAS) | 3 months post-partum and 12 months post-partum | |
Secondary | Self-efficacy | Self-efficacy will be measured using the Generalized Self-Efficacy scale, developed by Schwarzer and Jerusalem | 3 months post-partum and 12 months post partum | |
Secondary | Perceived decision making | Questions pertaining to perceived decision-making are from the Pakistan Demographic and Health Survey (PDHS) | 3 months post-partum and 12 months post partum | |
Secondary | Perceived social support | Perceived social support will be measured using the Multi-dimensional Scale of Perceived Social Support (MSPSS), developed by Zimet et al. | 3 months post-partum and 12 months post partum | |
Secondary | Maternal demographics | Questions pertaining to demographic data are adapted from the Pakistan Demographic and Health Survey (PDHS) | 8-20 weeks post-conception | |
Secondary | Food insecurity | Questionnaire developed by Hager, E.R., et al., Development and validity of a 2-item screen to identify families at risk for food insecurity. | 8-20 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Perceived parental stress | Perceived parental stress will be measured using the Perceived Stress Scale (PSS-10) | 3 months post-partum and 12 months post partum | |
Secondary | Preterm birth | noted in labor and birth chart review | Within 24 hours of birth | |
Secondary | Stillbirth | noted in labor and birth chart review | Within 24 hours of birth | |
Secondary | Small for gestational age | noted in labor and birth chart review | Within 24 hours of birth | |
Secondary | Large for gestational age | noted in labor and birth chart review | Within 24 hours of birth | |
Secondary | Birth size: length | Measured in cm | within 24 hours of birth | |
Secondary | Birth size: head circumference | Measured in cm | within 24 hours of birth | |
Secondary | Birth size: weight | Measured in kg | within 24 hours of birth | |
Secondary | Birth defects | Assessed within 24 hours of birth | within 24 hours of birth | |
Secondary | Delivery assessment | Assessed within 24 hours of birth | within 24 hours of birth | |
Secondary | Infant dietary intake: NutricheQ Questionnaire | NutricheQ questionnaire: a tool designed for toddlers aged 1 to 3 years of age, with a focus on markers for inadequate or excessive intake and dietary imbalances | 12 months | |
Secondary | Maternal stool biomarkers: Calprotectin, Lipocalin and Claudin 15 | Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Infant Stool biomarkers: Calprotectin, Lipocalin and Claudin 15 | Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers | 3 months and 12 months | |
Secondary | Maternal: incidence of pathobionts | As identified through 16S, 18S and ITS rDNA surveys | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Infant: incidence of pathobionts | As identified through 16S, 18S and ITS rDNA surveys | 3 months and 12 months | |
Secondary | Maternal: metabolomic profile of stool (metabolites involved in central metabolism as analysed by Mass Spectrometry) | Analysis of the core metabolites involved in central metabolism. These metabolites will be analysed through Mass Spec and include short chain fatty acids, amino acids, intermediates in energy metabolism and nucleotide biosynthesis | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Maternal gut bacteria profile as measured through 16S rDNA sequence surveys | measured through 16S rDNA sequence surveys | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Maternal: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25) | TMIC Metallomics Platform to be used. | 8-20 weeks post conception, 30-34 weeks post conception, and 12 months post partum | |
Secondary | Infant: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25) | Through TMIC platform | 12 months | |
Secondary | Infant: gut bacterial profile as measured through 16S rDNA sequence surveys | measured through 16S rDNA sequence surveys | 3 and 12 months post partum | |
Secondary | Maternal metabolic pathway expression profile as measured through whole microbiome RNASeq (metatranscriptomics) | measured through whole microbiome RNASeq (metatranscriptomics) | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Infant eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys | measured through 18S and ITS rDNA sequence surveys | 3 months and 12 months | |
Secondary | Maternal eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys | measured through 18S and ITS rDNA sequence surveys | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Maternal bacterial gene expression profile as measured through whole microbiome RNASeq (metatranscriptomics) | The output of these analyses are readouts of microbial gene expression detailing biochemical activities as well as the taxa responsible. | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Maternal: microbiome taxonomic alpha and beta diversity | To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances. | 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum | |
Secondary | Infant: microbiome taxonomic alpha and beta diversity | To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances. | 3 months and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT06258902 -
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
|
||
Completed |
NCT05487196 -
Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia
|
Phase 2 | |
Completed |
NCT03750968 -
Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects
|
Phase 2 | |
Enrolling by invitation |
NCT06127277 -
Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care
|
N/A | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Recruiting |
NCT05899101 -
The Impact of Opioid and Cannabis Exposure on Fetal Growth
|
||
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Completed |
NCT04296396 -
Opioid Prescription After Cesarean Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069869 -
Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069856 -
Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06079918 -
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
|
Phase 3 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A |